Lurasidone Hcl
Brand names: Latuda, Lurasidone Hcl
At a glance
- Medicare prescriptions, 2024
- 671,538
- Medicare drug cost
- $162.8M
- Average cost per prescription
- $242
- Clinicians who prescribed it
- 21,561
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Lurasidone hydrochloride tablets are indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia. Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression). Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression).
From the FDA-approved prescribing information (label dated December 2024). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lurasidone hydrochloride is not approved for the treatment of patients with dementia-related psychosis. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatry 40.2%
- Psychiatric Nurse Practitioners 34.7%
- Nurse Practitioners 8.0%
- Physician Assistants 5.5%
- Family Medicine 4.2%
- Internal Medicine 3.2%
- Child & Adolescent Psychiatry 1.9%
- Geriatric Medicine 0.5%
- Neurology 0.4%
- General Practice 0.3%
- Addiction Medicine 0.2%
- Pharmacists 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 0% from 2019 to 2024.
Biggest change by state since 2019
- Arizona +26%
- Kentucky +22%
- West Virginia +15%
- Virginia +15%
- Oregon +13%
- Mississippi (smallest change) −27%
- Missouri (smallest change) −14%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Direct_rx
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | white round tablet, 8 mm | L 26 |
Sumitomo Pharma America, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 20 mg | white round tablet, 6 mm | L 20 |
| 40 mg | white round tablet, 8 mm | L 40 |
| 60 mg | white oval tablet, 13 mm | L 60 |
| 80 mg | green oval tablet, 12 mm | L 80 |
| 120 mg | white oval tablet, 15 mm | L 120 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $5,492 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Sumitomo Pharma Co., LTD. $5,492
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Jan 2024 · Sun Pharmaceutical Industries Inc · Class II
CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Industry-funded trials
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.